Abstract
9024 Background: IM is a highly effective treatment for metastatic/unresectable GIST. Although pts may exhibit durable systemic disease control, with time clonal evolution of lesions refractory to IM emerge and require alternative treatment approaches. We have evaluated the role of percutaneous RFA in this subset of pts with single or oligoclonal progressing GIST lesions who are in good performance status. Methods: Pts with limited sites of GIST progressing despite continuation of IM were treated with CT-guided RFA. All pts had staging with CT/MRI as well as functional imaging with 18FDG PET scans, both before and after RFA. Biopsy of the target lesions was performed before RFA. Results: Nine pts treated with imatinib for a median of 25 months (m) (range 18–36 m) underwent RFA for single or limited site(s) of progressing disease. Sites of progression: 8/9 pts with liver metastases, 1/9 with soft tissue disease. 5/9 of these pts developed a new nodule within a pre-existing GIST lesion, the remaining 4/9 ha...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.